HETE is the endogenous agonist for G protein-coupled receptor 39 (GPR39) in vascular smooth cells, so researchers ...

The enzyme aminocarboxymuconate semialdehyde decarboxylase (ACMSD) is a regulator of de novo NAD+ synthesis and is reduced in ...

Discovered and characterized at The University of North Carolina at Chapel Hill, the compound showed potent PDE4D inhibition ...

To address limitations with CAR T therapies targeting CD19, Allogene Therapeutics Inc. has developed ALLO-329, a ...

Previous laboratory and clinical studies showed that inhibiting the activation of the MAPK signaling pathway could attenuate acute lung injury.

Oxford Nanopore Technologies Ltd. has established a new collaboration with UK Biobank to create the world’s first ...

Our immune cells are not just “defenders” against deadly viruses and pathogens but also a great balancer for tissue ...

The FDA announced a new pilot program for communication of medical device recalls, but industry may be wary of a program that ...

The first day of the U.S. FDA’s two-day advisory hearing on generative artificial intelligence reflected some of the ...

Researchers from Anaveon AG and affiliated organizations presented the discovery and preclinical characterization of ANV-700, a novel proximity-activated cytokine (PAC) compound designed to ...

Researchers from EMD Serono Research and Development Institute Inc. hypothesized that modulation of two T-cell costimulatory pathways, such as CD28 and OX40, in one single molecule would be more ...

Empyrean Therapeutics Inc. has acquired a first-in-class TLR2 antagonist molecule from Eos Therapies Inc. with the aim of ...